Gilead Targets Lupin Over Generic Ranexa

Law360, New York (July 15, 2010, 2:34 PM EDT) -- Biopharmaceutical company Gilead Sciences Inc. has fired off a patent infringement suit against Lupin Ltd., seeking to block the Indian generic-drug maker from offering a copycat version of chronic chest pain treatment Ranexa.

Foster City, Calif.-based Gilead said Wednesday it had filed suit in the U.S. District Court for the District of New Jersey in response to Lupin's abbreviated new drug application asking the U.S. Food and Drug Administration for approval to make and market ranolazine extended-release tablets before the expiration of the plaintiff's patents for...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.